Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib

1. Herraez, E.
2. Lozano, E.
3. Macias, R.I.R.
4. Vaquero, J.
5. Bujanda, L.
6. Banales, J.M.
7. Marin, J.J.G.
8. Briz, O.